# Antibody Drugs Sector Canonical URL: https://biopharmsignal.com/sector/antibody-drugs Antibody Drugs includes companies developing monoclonal antibodies or related antibody-based therapeutics. These assets are central to many oncology, immunology, and rare-disease franchises because they can offer target specificity and scalable biologic development paths. Companies currently grouped under Antibody Drugs: 29 ## Recent Sector News - 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc - 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc - 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc - 2026-07-14 12:00 EST — PMN — [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-5218a89a) — Source: ProMIS Neurosciences - 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc - 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc - 2026-07-09 10:00 EST — GSK — [Roy Jakobs to join GSK Board as Non-Executive Director](https://biopharmsignal.com/news/GSK/roy-jakobs-to-join-gsk-board-as-non-executive-director-560f2019) — Source: GSK plc - 2026-07-09 03:08 EST — IFRX — [Press Release](https://biopharmsignal.com/news/IFRX/press-release-21192d48) — Source: Inflarx NV - 2026-07-09 03:08 EST — IFRX — [Press Release](https://biopharmsignal.com/news/IFRX/press-release-1bfd0518) — Source: Inflarx NV - 2026-07-09 03:08 EST — IFRX — [Press Release](https://biopharmsignal.com/news/IFRX/press-release-4e99a1d1) — Source: Inflarx NV - 2026-07-09 03:08 EST — IFRX — [Press Release](https://biopharmsignal.com/news/IFRX/press-release-f168c076) — Source: Inflarx NV - 2026-07-09 03:08 EST — IFRX — [Press Release](https://biopharmsignal.com/news/IFRX/press-release-34f26021) — Source: Inflarx NV - 2026-06-25 20:05 EST — REGN — [Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast](https://biopharmsignal.com/news/REGN/regeneron-to-report-second-quarter-2026-financial-and-operating-results-and-host-c2e371f6) — Source: Regeneron Pharmaceuticals - 2026-06-25 13:46 EST — GSK — [GSK announces commencement of tender offer to acquire Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-announces-commencement-of-tender-offer-to-acquire-nuvalent-inc) — Source: GSK plc - 2026-06-25 13:46 EST — REGN — [Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)](https://biopharmsignal.com/news/REGN/cemdisiran-regulatory-submissions-accepted-for-review-by-fda-and-ema-for-the-treatment-of-generalized-myasthenia-gravis-gmg) — Source: Regeneron Pharmaceuticals - 2026-06-25 13:46 EST — GSK — [Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)](https://biopharmsignal.com/news/GSK/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis) — Source: GSK plc - 2026-06-25 13:46 EST — GSK — [GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome](https://biopharmsignal.com/news/GSK/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-syndrome) — Source: GSK plc - 2026-06-25 13:46 EST — CRVS — [Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China](https://biopharmsignal.com/news/CRVS/corvus-pharmaceuticals-announces-additional-investment-in-angel-pharmaceuticals-to-advance-the-development-of-soquelitinib-in-china) — Source: Corvus Pharmaceuticals - 2026-06-25 13:46 EST — GSK — [GSK enters agreement to acquire Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-enters-agreement-to-acquire-nuvalent-inc) — Source: GSK plc - 2026-06-25 13:46 EST — REGN — [Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO](https://biopharmsignal.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo) — Source: Regeneron Pharmaceuticals ## Companies - [ADAG](https://biopharmsignal.com/company/ADAG) — Adagene - [ADCT](https://biopharmsignal.com/company/ADCT) — ADC Therapeutics - [AFMD](https://biopharmsignal.com/company/AFMD) — Affimed - [ALLK](https://biopharmsignal.com/company/ALLK) — Allakos - [AMAM](https://biopharmsignal.com/company/AMAM) — Ambrx Biopharma - [ARGX](https://biopharmsignal.com/company/ARGX) — Argenx - [CASIF](https://biopharmsignal.com/company/CASIF) — CASI Pharmaceuticals Inc - [CASI](https://biopharmsignal.com/company/CASI) — CASI Pharmaceuticals Inc - [CMPX](https://biopharmsignal.com/company/CMPX) — Compass Therapeutics - [CRVS](https://biopharmsignal.com/company/CRVS) — Corvus Pharmaceuticals - [CTMX](https://biopharmsignal.com/company/CTMX) — CytomX Therapeutics, Inc. - [GMAB](https://biopharmsignal.com/company/GMAB) — Genmab - [GSK](https://biopharmsignal.com/company/GSK) — GSK plc - [IMGN](https://biopharmsignal.com/company/IMGN) — ImmunoGen - [IMNM](https://biopharmsignal.com/company/IMNM) — Immunome - [IMRN](https://biopharmsignal.com/company/IMRN) — Immuron - [IFRX](https://biopharmsignal.com/company/IFRX) — Inflarx NV - [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation - [MRUS](https://biopharmsignal.com/company/MRUS) — Merus - [OABI](https://biopharmsignal.com/company/OABI) — OmniAb - [PMN](https://biopharmsignal.com/company/PMN) — ProMIS Neurosciences - [HGEN](https://biopharmsignal.com/company/HGEN) — QHUMANIGEN INCD - [REGN](https://biopharmsignal.com/company/REGN) — Regeneron Pharmaceuticals - [SNY](https://biopharmsignal.com/company/SNY) — Sanofi - [SYRE](https://biopharmsignal.com/company/SYRE) — Spyre Therapeutics, Inc. - [SURF](https://biopharmsignal.com/company/SURF) — Surface Oncology - [STRO](https://biopharmsignal.com/company/STRO) — Sutro Biopharma - [VINC](https://biopharmsignal.com/company/VINC) — Vincerx Pharma - [XNCR](https://biopharmsignal.com/company/XNCR) — Xencor